www.diabetesclinic.ca 2003 CDA Clinical Practice Guidelines ORAL AGENTS J. Robin Conway M.D. Diabetes Clinic - Smiths Falls, ON Options for Diabetes www.diabetesclinic.ca Kingston April 17 2004
Jan 14, 2016
www.diabetesclinic.ca
2003 CDA Clinical Practice Guidelines ORAL AGENTS
J. Robin Conway M.D.Diabetes Clinic - Smiths Falls, ON
Options for Diabetes
www.diabetesclinic.ca
Kingston April 17 2004
www.diabetesclinic.ca
80
70
60
50
40
30
20
10
0
Prevalence (millions)
North America
Europe SoutheastAsia
Year199520002025
World Health Organization. 1997.Canadian Diabetes Association, 1998 website.
Worldwide rates of diabetes mellitus: predictions
www.diabetesclinic.ca
Frequency of diagnosed and undiagnosed diabetes and IGT, by age (U.S. data - Harris)
2 Million Canadians Have Diabetes Mellitus
0
5
10
15
20
25
30
35
40
20-34 35-44 45-54 55-64 65-74
% ofpopulation
IGTUndiagnosed diabetesDiagnosed diabetes
Harris. Diabetes Care 1993;16:642-52.
www.diabetesclinic.caHaffner Am J Cardiol 1999;84:11J-4J.
Framingham study: diabetes and CAD mortalityat 20-year follow-up
Cardiovascular Disease Risk is Increased 2 to 4 Times
17.4
8.5
17.0
3.602468
101214161820
Annual CAD Deaths per 1,000
Persons
Men Women
Diabetics Nondiabetics
www.diabetesclinic.ca
The burden of Diabetes• 87% of Type 2 Diabetes is managed
in Primary Care
• Diascan Study: 23.5% of patients in our office have diabetes
• Quebec screening >2 Risk Factors, 79% tested 7% Diabetes , 13% IGT or IFG
74% No Treatment AdviceStrychar I et al. Cdn J Diab 2003(abs)
Leiter et al. Diabetes Care 2000
www.diabetesclinic.ca
T2DM in Family Practice
• 84% of patients had A1c in past year
• Average A1c 7.9% (goal<7%)
• 88% had BP check
• 48% had lipid profiles
• 28% tested for microalbuminuria
• 15% had foot examsHarris S et al. Cdn Fam Phys 2003
www.diabetesclinic.ca
Organization and Delivery of Care
• Diabetes should be organized using a DHC (Diabetes Healthcare) team approach
• People with diabetes should be offered initial and
ongoing needs-based diabetes education• The role of diabetes nurse educators and other
DHC team members should be enhanced in cooperation with the physician
www.diabetesclinic.ca
Structured care
• ACLS
• ATLS
• Seattle Defibrillator Experience
• GREACE Study
www.diabetesclinic.ca
Structured Care VS Usual Care
Αthyros VG et al. Curr Med Res Opin. 2002;18:220-228.
• Patients received atorvastatin 10 mg/d (titrated up to 80 mg/d) to reach the NCEP LDL-C goal
• Specialist care unit with a strict protocol to achieve NCEP LDL-C target
• Treatment from a physician of pt’s choice• All patients had access to any necessary medications,
including statins• Included lifestyle modifications (diet and exercise) as well
as lipid-lowering medications
Str
uctu
red
Car
e:U
sual
Car
e:
www.diabetesclinic.ca
Reduction in Relative Risk of Primary Endpoints
-43
-59
-52 -51 -50-47-47
-60
-50
-40
-30
-20
-10
0Total Mortality
CoronaryMortality Nonfatal MI
UnstableAngina PTCA/CABG CHF Stroke
Αthyros VG et al. Curr Med Res Opin. 2002;18:220-228.
%% R
edu
ctio
n R
edu
ctio
n
PP==00.0021.0021 PP==00.001.00177 PP=0=0.00.001111 PP==00.0.03434PP==00.00.000101 PP==00.00.003232 PP=0=0.0.02121
www.diabetesclinic.ca
Recommended targets for glycemic control*
A1C**(%)
FPG/preprandial PG(mmol/L)
2-hour postprandial PG(mmol/L)
Target for most patients 7.0 4.0-7.0 5.0-10.0
Normal range (considered for patients in whom it can beachieved safely)
6.0 4.0-6.0 5.0-8.0
*Treatment goals and strategies must be tailored to the patient, with consideration given to individual risk factors.†Glycemic targets for children 12 years of age and pregnant women differ from these targets. Please refer to “Other Relevant Guidelines” for further details.**An A1C of 7.0% corresponds to a laboratory value of 0.070. Where possible, Canadian laboratories should standardize theirA1C values to DCCT levels (reference range: 0.040 to 0.060). However, as many laboratories continue to use a differentreference range, the target A1C value should be adjusted based on the specific reference range used by the laboratory thatperformed the test. As a useful guide: an A1C target of 7.0% refers to a threshold that is approximately 15% above the upper limit of normal.
A1C = glycosylated hemoglobinDCCT = Diabetes Control and Complications TrialFPG = fasting plasma glucosePG = plasma glucose
www.diabetesclinic.ca
Physical Activity and Diabetes
• For people who have not previously exercised regularly and are at risk of CVD, an ECG stress test should be considered prior to starting an exercise program
Type Recommendation Example
Aerobic – especially type 2
• 150 minutes of moderate- intensity exercise each week
• 3 spread out over at least non- consecutive days
• 4 gradually increase to hours or more aweek
• 10 sessions should be at least minutes at a time
B risk walking Biking
Raking leaves Continuous swimming
Dancing Water aerobics
Resistance– all persons with, diabetes including elderly
• 3 times a week • 1 10start with set of-15 repetitions • 2 10progress to sets of-15 • 3 8then sets of
Weight lifting Exercis e with weight machines
Testing is particularly important before, during and for many hours after exercise.
www.diabetesclinic.ca
Nutrition TherapyPeople with diabetes should:
• Receive nutrition counseling by a registered dietitian
• Receive individualized meal planning
• Follow Canada’s Guidelines for Healthy Eating
• People on intensive insulin should also be taught to adjust the insulin for the amount of carbohydrate consumed
www.diabetesclinic.ca
Drugs in Type 2
www.diabetesclinic.ca
9
Hb
A1
c (
%)
UKPDS: Long-term Glucose Control
06
7
8
0 3 6 9 12 15Years of treatment
Conventional
Intensive
ULN = 6.2%
UKPDS Study Group, Lancet, 1998;352:837-853.
www.diabetesclinic.ca
06
7
8
9
2 4 6 8 10
A1
C (
%)
Years from randomization
Upper limit of normal = 6.2%
ConventionalGlyburideChlorpropamideMetforminInsulin
0
UK Prospective Diabetes Study Group. UKPDS 34. Lancet 1998; 352:854–865.
Overweight patientsCohort, median values
UKPDS demonstrated loss of glycemic control
with all agents studied
www.diabetesclinic.ca
-ce
ll f
un
ctio
n (
%)
Conventional Sulphonylurea Metformin
0
20
40
60
80
100
0 1 2 3 4 5 6 70
20
40
60
80
100
0 1 2 3 4 5 6 7
-ce
ll f
un
ctio
n (
%)
Years from randomization
Non obese Obese
UKPDS 16: Diabetes 1995; 44:1249–1258
Progressive Loss of -cellFunction in UKPDS
Mean age at baseline 53 yrs.
www.diabetesclinic.ca
Natural History of Type 2 Diabetes
Normal Impaired glucosetolerance 10 yrs
Type 2 diabetes12-15 yrs
Time
Insulinresistance
Insulinproduction
Glucoselevel
-celldysfunction
Henry. Am J Med 1998;105(1A):20S-6S.
LifestyleMetformin/ThiazolidinedionesMetformin/Thiazolidinediones
SecretagoguesSecretagoguesInsulinInsulin
www.diabetesclinic.ca
Sites of Action of Currently Available Therapeutic Options
GLUCOSE ABSORPTION
GLUCOSE PRODUCTION
BiguanidesThiazolidinediones
MUSCLE
PERIPHERAL GLUCOSE UPTAKE
Thiazolidinediones(Biguanides)
PANCREAS
INSULIN SECRETIONSulfonylureasMeglitinides
Insulin
ADIPOSE TISSUE
LIVER
Alpha-glucosidase inhibitors
INTESTINE
Sonnenberg, Kotchen Curr Opin Nephrol Hypertens 1998;7:551-5.
www.diabetesclinic.ca
Combination Antihyperglycemic Therapy
Site of action MOA Agents
Insulin
secretion
Sulfonylureas Meglitanides,
Insulin
Glucose
production Biguanides
Thiazolidinediones
Glucose
absorption Alpha-glucosidase
inhibitors
Peripheral glucose uptake
Thiazolidinediones (Biguanides)
Addition, rather than substitution recommended
Agents from other classes should be added
–Diff sites of action
–Diff MOA
www.diabetesclinic.ca
Individualized Treatment
• Metformin for overweight patients
• If control not achieved add another agent
• If A1c >9 start with 2 agents
• Consider early insulin for hyperglycemia
• Bedtime intermediate insulin (NPH)
www.diabetesclinic.ca
Clinical assessment and initiation of nutrition and physical activity
Mild to moderate hyperglycemia (A1C <9.0%)
Overweight(BMI 25 kg/m2)
Non-overweight(BMI 25 kg/m2)
Biguanide alone or incombination with 1 of:
• insulin sensitizer*• insulin secretagogue• insulin• alpha-glucosidase inhibitor
1 or 2† antihyperglycemicagents from differentclasses
• biguanide• insulin sensitizer*• insulin secretagogue• insulin• alpha-glucosidase inhibitor
Add a drug from a different class orUse insulin alone or in combination with:
• biguanide• insulin secretagogue• insulin sensitizer*• alpha-glucosidase inhibitor
Marked hyperglycemia (A1C 9.0%)
2 antihyperglycemic agentsfrom different classes †
• biguanide• insulin sensitizer*• insulin secretagogue• insulin• alpha-glucosidase inhibitor
Basal and/orpreprandial insulin
Add an oral
antihyperglycemic agentfrom a differentclass of insulin*
Intensify insulinregimen or add
• biguanide• insulin secretagogue**• insulin sensitizer*• alpha-glucosidase inhibitor
L
I
F
E
S
T
Y
L
E
Timely adjustments to and/or additions of oral antihyperglycemic agentsand/or insulin should be made to attain target A1C within 6 to 12 months
If not at target If not at target If not at target If not at target
www.diabetesclinic.ca
Clinical assessment and initiation of nutrition and physical activity
Mild to moderate hyperglycemia (A1C <9.0%)
Overweight(BMI 25 kg/m2)
Biguanide alone or incombination with 1 of:• insulin sensitizer*• insulin secretagogue• insulin• alpha-glucosidase inhibitor
Add a drug from a different class orUse insulin alone or in combination with:• biguanide• insulin secretagogue• insulin sensitizer*• alpha-glucosidase inhibitor
Marked hyperglycemia (A1C 9.0%)
2 antihyperglycemic agentsfrom different classes †
• biguanide• insulin sensitizer*• insulin secretagogue• insulin• alpha-glucosidase inhibitor
Basal and/orpreprandial insulin
Add an oral
antihyperglycemic agentfrom a differentclass of insulin*
If not at targetIf not at target
Intensify insulinregimen or add
• biguanide• insulin secretagogue**• insulin sensitizer*• alpha-glucosidase inhibitor
Non-overweight(BMI 25 kg/m2)
1 or 2† antihyperglycemicagents from differentclasses
• biguanide• insulin sensitizer*• insulin secretagogue• insulin• alpha-glucosidase inhibitor
If not at target
Timely adjustments to and/or additions of oral antihyperglycemic agentsand/or insulin should be made to attain target A1C within 6 to 12 months
L
I
F
E
S
T
Y
L
E
If not at target
www.diabetesclinic.ca
Add a drug from a different classor
Use insulin alone or in combination with:• biguanide• insulin secretagogue• insulin sensitizer*• alpha-glucosidase inhibitor
Mild to moderate hyperglycemia (A1C <9.0%)
Timely adjustments to and/or additions of oral antihyperglycemic agentsand/or insulin should be made to attain target A1C within 6 to 12 months
•When used in combination with insulin, insulin sensitizers may increase the risk of edema or CHF. The combination •of an insulin sensitizer and insulin is currently not an approved indication in Canada.
If not at target
Biguanide alone or in combination with 1 of:
• insulin sensitizer*• insulin secretagogue• insulin• alpha-glucosidase inhibitor
Overweight (BMI 25 kg/m2)
L
I
F
E
S
T
Y
L
E
www.diabetesclinic.ca
Pharmacotherapy• Metformin• Insulin Sensitizer (TZD)• Insulin Secretagogue• Insulin• Alpha-glucosidase inhibitor• Anorexiant*• If not at target• Add an agent from another class
www.diabetesclinic.ca
Pharmacotherapy• Treat the Predominant problem
• Each Drug will lower A1c 1-1.5% (Acarbose & Orlistat 0-5%)
• Start with Metformin in Obese or High FBS
• Combination therapy if A1c >9%
• Early Insulin if decompensated
• Consider TZD
www.diabetesclinic.ca
-2.5
-2
-1.5
-1
-0.5
0
Glyburide
Hb
AH
bA
1C1C (
%)
(%
)
Metformin AcarboseGlitazoneRepaglinide
HbA1C in Diet-Treated PatientsEffects of Various Medications
(Difference from Placebo)(Difference from Placebo)
FDA approved Prescribing Information for various OADs
www.diabetesclinic.ca
Oral Agents for Type 2 Diabetes
SMBG is recommended at least once daily
• Combination at less than maximal doses result in more rapid improvement of blood glucose
• Counsel patients about hypoglycemia prevention and treatment
Class Expected decrease in A1C with monotherapy
Álpha-glucosidase inhibitor 0.5 – 0.8
Biguanide 1.0 – 1.5
Insulin Depends on regimen
Insulin secretagogues 1.0 – 1.5 0.5 for nateglinide
Insulin sensitizers (TZDs) 1.0 – 1.5
Combined rosiglitazone and metformin 1.0 – 1.5
Antiobesity agent (orlistat) 0.5
Canadian Diabetes Association 2003 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada. Cdn J Diabetes 2003; 27 (suppl 2)
www.diabetesclinic.ca
Pharmacologic Management of Type 2 Diabetes
• Add anti-hyperglycemic agents if:
Diet & exercise therapy do not achieve targets after 2-3 month trialor
newly diagnosed and has an A1C of 9
Intensify to reach targets in 6-12 months
A1C & BMI Suggested starting agent
< 9%BMI 25 Biguanide alone or in combination
BMI < 25 1 or 2 agents from different classes
9% --2 agents from different classes or insulin basal and/or preprandial
www.diabetesclinic.ca
Need for Combination Therapy in UKPDS
50%
75%
0%
10%
20%
30%
40%
50%
60%
70%
80%
3 years 9 years
% of Patients
www.diabetesclinic.ca
Dose-Response Curve
Riddle M. Combining sulfonylureasand other oral agents. Am J of Med2000; 108(6A):15S-22S .
Dose-response curve showing GI related effects
30
20
10
0 500 1000 1500 2000 2500
0
0.5
1.0
1.5
2.0
Dose
GI
Dis
tre
ss
Pa
tie
nts
(%
)
Re
du
cti
on
vs
. p
lac
eb
o,
Hb
A 1c (%
)
Metformin
www.diabetesclinic.ca
Mechanisms To Lower Glucose• Decrease glucose production:
biguanides (or thiazolidinediones)
• Increase muscle glucose uptake: thiazolidinediones (or biguanides)
• Stimulate insulin secretion: repaglinide or sulfonylureas
• Retard carbohydrate absorption: alpha-glucosidase inhibitors
• Correct insulin deficiency: insulin or insulin analogues
www.diabetesclinic.ca
Biguanides: mechanism of action
1. Intestine:glucose absorption
2. Muscle and adipose tissue: glucose uptake Metformin glucose utilization
3. Pancreas: insulin secretion
4. Liver: hepatic glucose output Metformin HGO
Insulin resistance
Insulin resistanceBlood
glucose
www.diabetesclinic.ca
Metformin – Advantages –
• Corrects a primary pathophysiologic impairment: hepatic glucose production
• High initial response rate
• Long record of relative safety
• No weight gain or modest weight loss
• Advantageous lipid profile
www.diabetesclinic.ca
Metformin – Disadvantages –
• GI side effects on initiation• Must be held prior to, and after, radiologic studies
using intravascular iodinated contrast media• Risk of lactic acidosis: caution in
– impaired renal function
– impaired hepatic function
– pharmacologically treated CHF
– alcoholism
www.diabetesclinic.ca
Metformin Dosage
• 500-2500 mg/day, no benefit over 2000 mg/day. Divide dose into twice daily. Tablets of 500 & 850 mg. 500 mg fully covered by ODB, 850 mg (Glucophage) not covered.
• Start low and titrate up slowly to avoid GI side effects
www.diabetesclinic.ca
Thiazolidinediones: mechanism of actions
Muscle and
adipose tissue insulin resistance glucose uptake
Liver insulin resistance hepatic glucose
production
Bloodglucose
Pancreas demand for insulin secretion ß-cell insulin content
www.diabetesclinic.ca
Thiazolidinediones – Advantages –
• Corrects a primary pathophysiologic impairment: insulin resistance
• Possible once-daily dosing
• Improves Lipids, Lower serum triglyceride
• May be used in renal insufficiency
www.diabetesclinic.ca
Thiazolidinediones – Disadvantages –
• Delayed action (onset: 3 wks, full effect:10-12 wks)
• Variable response in monotherapy
• Weight gain
• Increased LDL-cholesterol (short-term)
• Few long-term studies
www.diabetesclinic.ca
Thiazolidenedione Dosage
• Pioglitazone (Actos), dosage range 15-45 mg
• Tablets of 15, 30 & 45 mg
• Rosiglitazone (Avandia) dose range 2-8 mg Tablets of 2, 4, 8 mg
• May take 3 weeks to 3 mo to see effect
• ODB Section 8 with failure of max dose Metformin & Glyburide
www.diabetesclinic.ca
Sulfonylureas: mechanism of action
1. Intestine:glucose absorption
2. Muscle and adipose tissue: glucose uptake
3. Pancreas: Insulin secretionSulfonylureas insulin secretion
4. Liver: hepatic glucose output
Insulin resistance
Insulin resistanceBlood
glucose
www.diabetesclinic.ca
Sulfonylureas – Advantages –
• Improve a primary pathophysiologic impairment: insulin secretion
• Physiologic route of insulin delivery
• High initial response rate
• No lag period before response
www.diabetesclinic.ca
Sulfonylureas – Disadvantages –
• Hypoglycemia– may be prolonged or severe
• Weight gain
• Drug interactions (especially 1st generation)
• Hyponatremia (with chlorpropamide)
• Cannot use if allergic to sulfa compounds
www.diabetesclinic.ca
Sulphonylureas Dosage
• Glyburide (Diabeta)dose range 2.5-20 mg, split into twice daily. Tablets of 2.5 and 5 mg Full ODB Coverage
• Gliclazide (Diamicron) dose range 40-320 mg a day, divided into 2 doses. Diamicron MR 30 mg from 1-4 tablets, once daily ODB section 8 if hypoglycemia on Glyburide
• Glimepiride (Amaryl) dose 0.5-4 mg OD Tabs 0.5, 1 , 2, 4 mg. No ODB coverage
www.diabetesclinic.ca
MEGLITINIDES New Class of Insulin Secretagogues
Physiologic Reasons• Insulin secretion must be closely coupled to
fluctuations in plasma glucose with little or no lag time– Prevents early postprandial hyperglycemia– Prevents late postprandial hypoglycemia
• Insulin secretion should not be stimulated when plasma glucose is low
www.diabetesclinic.ca
Why is there a Need for New Classes of Insulin Secretagogues?
Pharmacologic Reasons• Chronic sulfonylurea treatment causes
desensitization of ß-cell insulin secretion
• High “secondary failure” rate with sulfonylureas
www.diabetesclinic.ca
Therapeutic Need, 1988
““In general, older patients have more renal In general, older patients have more renal failure and cardiovascular and hepatic failure and cardiovascular and hepatic problems, as well as a tendency to skip problems, as well as a tendency to skip meals and snacks. For this reason, it is meals and snacks. For this reason, it is best to choose an agent with relatively best to choose an agent with relatively short duration of action, which is less short duration of action, which is less
likely to cause profound hypoglycemia.”likely to cause profound hypoglycemia.”
Physician’s Guide to Non-Insulin-Dependent (Type II) Diabetes. Physician’s Guide to Non-Insulin-Dependent (Type II) Diabetes. Diagnosis and Diagnosis and Treatment (Second Edition) p.39. ADA-CEP 1984,1988.Treatment (Second Edition) p.39. ADA-CEP 1984,1988.
www.diabetesclinic.ca
Meglitinides Efficacy Summary
• Rapid response –Decline in 24-hr mean BG ( 2.2-4.4 mmol/L) within 1 week
• Good clinical response –Improves glucose control HbA1C ~ 1.6-2.1% (vs placebo)
• Glycemic control –Documented HbA1C reductions sustained over 1 year
• Dose response– Reductions in mean glucose seen at 0.5-4 mg ac
• Synergistic –Incremental improvements when used in combination with metformin
www.diabetesclinic.ca
Meglitinides Dosage
• Repaglinide (Gluconorm) 0.5 to 4 mg with each meal. Tablets of 0.5, 1.0 and 2 mg ODB Section 8 requires hypoglyhcemia on Glyburide
• Nateglinide (Starlix) 120 mg with each meal ODB No Coverage
www.diabetesclinic.ca
Insulin – Disadvantages –
• Hypoglycemia
• Weight gain
• Need for injections
• Non-physiologic route of administration (peripheral)
• Patient and physician non-acceptance
www.diabetesclinic.ca
Alpha-Glucosidase inhibitors mechanism of action
Amatruda, Diabetes Mellitus, 1996.
Insulin resistance
1. Intestine:glucose absorption
2. Muscle and adipose tissue: glucose
uptake
3. Pancreas: insulin secretion
4. Liver: hepatic glucose output
Insulin resistanceBlood glucose
www.diabetesclinic.ca
Alpha-Glucosidase Inhibitors – Advantages –
• Good safety profile
• No weight gain or modest weight loss
• Dose coupled to meals
www.diabetesclinic.ca
Alpha-Glucosidase Inhibitors - Disadvantages -
• Modest effect on fasting plasma glucose and HbA1C
• Flatulence, gastrointestinal side effects
• Cannot treat hypoglycemia with sucrose, maltose, or starch– use glucose, fructose, or lactose
www.diabetesclinic.ca
Acarbose Dosage
• Acarbose (Prandase) dose 50-100 mg with the first bite of each meal. High index of side effects, start low (25 mg OD) and titrate up gradually.
• Not very effective for hyperglycemia 0.5% A1c reduction.
• ODB Coverage on LU
www.diabetesclinic.ca
Anorexiants Dosage
• Orlistat (Xenical) 120 mg tabs, one with the first bite of each meal. Inhibits 30% of dietaryt fat absorpton needs to be used with a low fat diet. Lifestyle counseling essential. Prevented Diabetes in XENDOS study.
• ODB Section 8 with failure of Metformin & SU in the obese patient
• Sibutramine (Meridia) dose 10 or 15 mg caps OD. No ODB Coverage
www.diabetesclinic.ca
Type 2 Diabetes Key Concepts
• Dual impairment:– ß-cell function: insulin secretion– insulin action: insulin resistance
• “Glucose toxicity” aggravates both impairments
• Multiple mechanisms to correct hyperglycemia
• Most patients require combination therapy
www.diabetesclinic.ca
Combination Therapy Summary
• The magnitude of the diabetic epidemic dictates more aggressive approaches to treatment
• Evidence clearly suggest that early intensive treatment results in significant decrease in complications
• To reduce macrovascular disease more strict glucose control might be needed (HbA1c <6%)
www.diabetesclinic.ca
In Conclusion• Prevalence of type 2 diabetes is increasing
dramatically• Majority of patients are diagnosed and treated by
the family physician• New paradigm: need to be much more aggressive
early in the treatment of these patients utilizing dual therapies
• Hypoglycemia can be managed through proper treatment choices and lifestyle management
• Glucose is a continuous progressive risk factor for cardiovascular disease
www.diabetesclinic.ca
QUESTIONS?www.diabetesclinic.ca